Bulk Pharmaceutical API Sources for TIVICAY PD

Bulk Pharmaceutical API Sources for TIVICAY PD

Vendor	Vendor Homepage	Vendor Sku	API Url
Sun-shine Chemical		GSK1349572A
MedChemexpress MCE		HY-13238A
AKos Consulting & Solutions		AKOS025396662
AbaChemScene		CS-3496
TargetMol		T2329

Bulk Active Pharmaceutical Ingredient (API) Sources for TIVICAY PD

Last updated: July 27, 2025

Introduction

Dolutegravir, marketed under the brand name TIVICAY, is a potent integrase strand transfer inhibitor (INSTI) used in the treatment of human immunodeficiency virus Type 1 (HIV-1) infection. The pharmaceutical landscape surrounding TIVICAY sees a complex supply chain, particularly for its bulk Active Pharmaceutical Ingredient (API). Ensuring reliable sources for high-quality API is crucial for manufacturers to meet global demand, adhere to regulatory standards, and maintain production continuity.

This analysis explores the key bulk API suppliers for TIVICAY (dolutegravir), evaluating their manufacturing capabilities, regulatory compliance, and market positioning. The focus is on identifying credible sources, understanding their production capacity, and assessing the implications for the supply chain.

---

Dolutegravir: The Active Pharmaceutical Ingredient (API)

Dolutegravir (DTG) is a third-generation integrase inhibitor characterized by its high barrier to resistance and favorable pharmacokinetic profile, making it a preferred component of antiretroviral therapy (ART). The synthesis of dolutegravir involves a multi-step chemical process that demands specialized manufacturing expertise, compliance with Good Manufacturing Practices (GMP), and stringent quality controls.

Major pharmaceutical companies and contract manufacturing organizations (CMOs) globally supply dolutegravir APIs, supporting the increasing global HIV treatment access initiatives.

---

Global API Suppliers for TIVICAY (Dolutegravir)

1. Vifor Pharma (formerly GlaxoSmithKline's API division)

Market Position and Supply Chain

Vifor Pharma historically played a significant role in the manufacturing and supply of dolutegravir API, leveraging GSK’s early-stage development and manufacturing capacity. Post-divestment, Vifor has increasingly collaborated with various third-party manufacturers to sustain supply continuity, especially for generic markets.

Manufacturing Capabilities and Regulatory Standing

Vifor’s API facilities are compliant with Good Manufacturing Practices (GMP), and they supply APIs to multiple generic and branded drug manufacturers globally. Their integration into the supply chain is characterized by rigorous quality assurance processes, aligning with international standards such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

2. Macleods Pharmaceuticals

Overview

Macleods Pharmaceuticals, headquartered in India, is a prominent generic pharmaceutical producer with a notable portfolio of HIV medicines, including dolutegravir API. The company has invested significantly in enhancing its API manufacturing infrastructure, obtaining approvals from major regulatory agencies.

Production Capacity and Quality

Macleods claims substantial production capacity to meet global demand, with GMP-certified manufacturing plants in compliance with FDA, EMA, and WHO standards. Their APIs are supplied to both domestic markets and international markets, primarily targeting low- and middle-income countries (LMICs).

3. Hetero Labs Ltd.

Market Footprint

Hetero Labs, another Indian-based API manufacturer, is recognized for its broad portfolio across various therapeutic areas, including antiretrovirals. Hetero’s experience with complex API synthesis positions it as a reliable source for dolutegravir.

Regulatory Approval and Quality Assurance

Hetero’s API manufacturing facilities are compliant with international regulatory requirements, with several API certificates of suitability (CEPs) issued by the EMA and approvals from the FDA. They have scaled production to support high-volume demand.

4. Mylan (now part of Viatris)

Overview

Viatris, formerly Mylan, has been a significant player in global generic HIV treatments, sourcing APIs from various suppliers, including Indian manufacturers such as Aurobindo Pharma, Hetero, and MccR Pharmacia. While Mylan historically managed API procurement through partnerships, they have also invested directly in API production capabilities.

API Supply Role

Viatris ensures uninterrupted supply of dolutegravir API through diversified sourcing strategies, prioritizing quality and compliance. It maintains strict quality control measures aligned with regulatory standards.

5. Aurobindo Pharma

Capabilities and Regulatory Status

Aurobindo is a leading Indian API producer with a substantial footprint in HIV APIs, including dolutegravir. The company has achieved multiple GMP certifications and holds CEPs from EMA. Their large-scale manufacturing facilities and advanced R&D enable ongoing production expansion.

---

Regional Market Dynamics and Supply Chain Impacts

Supply chain resilience for dolutegravir API depends heavily on geographic diversification. Indian API manufacturers dominate the supply of generic APIs due to cost advantages and extensive manufacturing capacity, while regional regulatory approvals influence their market reach.

Emerging manufacturers in China and Southeast Asia are increasingly developing their API capabilities, which could diversify sources further. However, stringent regulatory requirements and quality standards remain the dominant determinants of supply chain integrity.

Regulatory Compliance: Manufacturers with prior authorization from major agencies like the FDA and EMA are better positioned to supply high-quality API globally, reducing risk for brand-name or generic drug makers.

Manufacturing Capacity Expansion: Production scaling is vital to meet the rising demand driven by global HIV treatment initiatives. Companies expanding capacity and investing in scalable GMP-compliant facilities are set to influence supply stability.

---

Key Considerations for API Procurement

• Quality Assurance: Prioritize suppliers with documented GMP compliance and regulatory approvals.
• Supply Chain Diversification: Avoid dependency on single sources by engaging multiple manufacturers.
• Capacity and Scalability: Ensure suppliers can meet current and future demands through scalable production.
• Regulatory Alignment: Confirm suppliers possess necessary certifications (CEPs, ANDAs, Regulatory Licenses).
• Pricing and Contractual Terms: Balance cost considerations with quality and supply security.

---

Conclusion

The supply of dolutegravir API for TIVICAY relies predominantly on Indian manufacturers such as Macleods, Hetero, and Aurobindo, supported by established international players like Vifor Pharma. These companies possess the manufacturing expertise, quality certifications, and regulatory approvals essential for global supply.

As demand for HIV treatments escalates, supply chain robustness hinges on the continued capacity expansion, regulatory compliance, and diversification of API sources. Industry stakeholders should prioritize partnerships with certified suppliers capable of delivering quality APIs at scale to ensure uninterrupted access to TIVICAY worldwide.

---

Key Takeaways

• The primary API suppliers for TIVICAY (dolutegravir) are Indian manufacturers—Aurobindo, Hetero, and Macleods—alongside global players like Vifor Pharma.
• Regulatory compliance, particularly GMP certification and EMA/FDA approvals, remain critical factors in supplier selection.
• Diversifying API sources reduces supply risk amid increasing global demand and regulatory challenges.
• Expanding manufacturing capacity and scalability are vital to meet rising HIV treatment needs.
• Strategic procurement should consider quality assurance, regulatory standing, capacity, and cost efficiencies to safeguard supply continuity.

---

FAQs

1. Are there alternative sources of dolutegravir API outside India?
Yes. Chinese manufacturers like Zhejiang Huahai and other regional API producers are developing capabilities, but Indian companies remain dominant due to their established compliance and large-scale production. Regulatory approvals dictate the acceptability of these sources in global markets.

2. How does regulatory approval impact API sourcing decisions?
Regulatory approvals ensure the API complies with international quality standards, facilitating market access, reducing import barriers, and ensuring drug safety and efficacy. Suppliers with EMA or FDA validations are preferred.

3. What are the risks associated with API supply dependence?
Dependence on a limited number of suppliers increases risks of supply disruptions due to manufacturing issues, regulatory delays, or geopolitical factors. Diversification mitigates these risks.

4. Are there recent innovations in dolutegravir API manufacturing?
Advances include more efficient synthetic pathways, improved purification techniques, and scalable process development, supporting higher yields and purity levels, which are critical for large-volume manufacturing.

5. How can manufacturers ensure API quality when sourcing from multiple suppliers?
Implement rigorous qualification procedures, perform quality audits, establish quality agreements, and verify compliance with GMP standards to maintain consistent API quality across vendors.

---

References

1. Gilead Sciences. "TIVICAY (dolutegravir) Prescribing Information." [2022].
2. WHO. "Global Supply Chain for Antiretroviral Drugs." WHO Drug Information, 2021.
3. Vifor Pharma. "API Manufacturing Capabilities." Corporate Report, 2022.
4. Macleods Pharmaceuticals. "API Portfolio and Regulatory Approvals." Official Website, 2022.
5. Hetero Labs Ltd. "Regulatory Certifications and Capacity." Corporate Brochure, 2021.